Novel Folate–Phenylfuran P‐gp Inhibitor Conjugates for Overcoming Multidrug Resistance in MCF‐7/ADR Cell
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500216 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Qin Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases & Anhui Center for Surveillance of Bacterial Resistance, The First Affiliated Hospital of Anhui Medical University,…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Folic Acid, Drug Resistance, Multiple, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Research Fund of Anhui Institute of translational Medicine, Anhui Province Scientific Research Planning Project.
Abstract (Originalsprache)
P‐glycoprotein (P‐gp) functions as a critical membrane transporter that drives tumor resistance by mediating drug efflux, ultimately contributing to multidrug resistance (MDR). Recently potent inhibitors have shown significant potential in countering chemotherapeutic resistance, particularly in breast cancer. However, P‐gp's presence in essential organs complicates clinical applications, underscoring the importance of developing tumor‐specific targeting strategies. Given the high‐level expression of folate receptors (FR) on the surface of breast cancer cells, this study conjugated a previously developed P‐gp inhibitor with folic acid, with the goal of harnessing FR‐mediated targeting for enhanced tumor cell specificity. In vitro evaluations reveal that the resultant conjugate maintains substantial resistance reversal efficacy against the MCF‐7/ADR breast cancer‐resistant cell line, comparable to the standalone inhibitor. The conjugate emerges as a highly potent and safe P‐gp inhibitor in xenograft mouse, likely attributable to its enhanced tumor‐targeting specificity, exhibiting superior in vivo efficacy when administered in combination with doxorubicin, relative to the original P‐gp inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases & Anhui Center for Surveillance of Bacterial Resistance, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- Anhui Province Key Laboratory of Infectious Diseases & Institute of Bacterial Resistance, Anhui Medical University, Hefei, 230022, China.
- School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, 999077, China.
ORCID-Profile: Yanyan Liu, Yasheng Li
Förderung
- National Natural Science Foundation of China
- Research Fund of Anhui Institute of translational Medicine
- Anhui Province Scientific Research Planning Project
- Anhui Province Clinical Medical Research Transformation Special Project
- Anhui University Natural Science Research Project
- The joint construction project of clinical medicine university and hospital
- China Primary Health Care Foundation
- Hong Kong Scholars Program
Zitieren
APA
Wang, Q., Yang, N., Yan, H., Zhu, Y., Zhang, Q., Zhu, R., Yang, Y., Yu, L., Liu, Y., Li, J., & Li, Y. (2025). Novel Folate–Phenylfuran P‐gp Inhibitor Conjugates for Overcoming Multidrug Resistance in MCF‐7/ADR Cell. ChemMedChem. https://doi.org/10.1002/cmdc.202500216
Vancouver
Wang Q, Yang N, Yan H, Zhu Y, Zhang Q, Zhu R, et al. Novel Folate–Phenylfuran P‐gp Inhibitor Conjugates for Overcoming Multidrug Resistance in MCF‐7/ADR Cell. ChemMedChem. 2025. doi:10.1002/cmdc.202500216
BibTeX
@article{Wang2025,
author = {Wang, Qin and Yang, Ning and Yan, Hui and Zhu, Yunzhu and Zhang, Qingyue and Zhu, Rongqing and Yang, Yi and Yu, Liang and Liu, Yanyan and Li, Jiabin and Li, Yasheng},
title = {Novel Folate–Phenylfuran P‐gp Inhibitor Conjugates for Overcoming Multidrug Resistance in MCF‐7/ADR Cell},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500216}
}
EUVIMED